Enrichment and expansion with nanoscale artificial antigen presenting cells for adoptive immunotherapy

K Perica, JG Bieler, C Schutz, JC Varela, J Douglass… - ACS …, 2015 - ACS Publications
K Perica, JG Bieler, C Schutz, JC Varela, J Douglass, A Skora, YL Chiu, M Oelke, K Kinzler
ACS nano, 2015ACS Publications
Adoptive immunotherapy (AIT) can mediate durable regression of cancer, but widespread
adoption of AIT is limited by the cost and complexity of generating tumor-specific T cells.
Here we develop an Enrichment+ Expansion strategy using paramagnetic, nanoscale
artificial antigen presenting cells (aAPC) to rapidly expand tumor-specific T cells from rare
naïve precursors and predicted neo-epitope responses. Nano-aAPC are capable of
enriching rare tumor-specific T cells in a magnetic column and subsequently activating them …
Adoptive immunotherapy (AIT) can mediate durable regression of cancer, but widespread adoption of AIT is limited by the cost and complexity of generating tumor-specific T cells. Here we develop an Enrichment + Expansion strategy using paramagnetic, nanoscale artificial antigen presenting cells (aAPC) to rapidly expand tumor-specific T cells from rare naïve precursors and predicted neo-epitope responses. Nano-aAPC are capable of enriching rare tumor-specific T cells in a magnetic column and subsequently activating them to induce proliferation. Enrichment + Expansion resulted in greater than 1000-fold expansion of both mouse and human tumor-specific T cells in 1 week, with nano-aAPC based enrichment conferring a proliferation advantage during both in vitro culture and after adoptive transfer in vivo. Robust T cell responses were seen not only for shared tumor antigens, but also for computationally predicted neo-epitopes. Streamlining the rapid generation of large numbers of tumor-specific T cells in a cost-effective fashion through Enrichment + Expansion can be a powerful tool for immunotherapy.
ACS Publications